Orphan drugs: Expensive yet necessary

QJM: An International Journal of Medicine

Volumn 108, Issue 4, 2015, Pages 269-272

  Hyry, H I ^a   Roos, J C P ^a   Cox, T M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

BUDGET; CLINICAL EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG LEGISLATION; DRUG SAFETY; FUNDING; GOVERNMENT; HEALTH CARE NEED; HEALTH CARE POLICY; HUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; RESOURCE ALLOCATION; SOCIETY; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; RARE DISEASES; SOCIAL JUSTICE; STATISTICS AND NUMERICAL DATA;

COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE RATIONING; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; SOCIAL JUSTICE;

EID: 84926459705     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu240     Document Type: Note

References (16)

1. Horton R, Lo S. Protecting health: the global challenge for capitalism. Lancet 2014; 383:577-8.
2. Black N. Can England's NHS survive? N Engl J Med 2013; 369:1-3.
3. Karanikolos M, Mladovsky P, Cylus J, Thomson S, Basu S, Stuckler D, et al. Financial crisis, austerity, and health in Europe. Lancet 2013; 381:1323-31.
4. Roos JCP, Hyry HI, Cox TM. Orphan drug pricing may warrant a competition law investigation. BMJ 2010; 341:c6471.
5. Philippidis A. The High Cost of Rare Disease Drugs - Sixfigure treatment prices continue to climb for orphan therapeutics. Genetic Engineering & Biotechnology News 4 March 2014.
6. Hyry HI, Stern AD, Cox TM, Roos JCP. Limits on use of health economic assessments for rare diseases. QJM 2014; 107:241-5.
7. Sandel MJ. Justice: What's the Right Thing to Do? London:Penguin Books, 2010.
8. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008; 371:2039-41.
9. Rawls J. Justice as Fairness: A Restatement. Cambridge, MA:Harvard University Press, 2001.
10. Daniels N. Democratic Equality: Rawls's complex egalitarianism. In: Freeman S, ed., The Cambridge Companion to Rawls. Cambridge: Cambridge University Press, 2003.
11. Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs 2014; 74:61-74.
12. Ginocchio VM, D'Amico A, Bertini E, Ceravolo F, Dardis A, Verrigni D, et al. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience. Mol Genet Metab 2013; 110:329-35.
13. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: break or bend? Is it time for a new evaluation for payers in Europe to take account of new rare disease treatments? Orphan J Rare Dis 2012; 7:74.
14. Chandra A, Jena AB, Skinner JS. The pragmatist's guide to comparative effectiveness research. J Econ Perspect 2011; 25:27-46.
15. Pearce F, Godfrey J. Evaluation of Highly Specialised Technologies for very rare diseases in England (http://www. rare-diseases.eu/wp-content/uploads/2013/08/139-t4.pdf).
16. Ross A. Will NHS case put arbitration under scrutiny? Global Arbitration Review 24 July 2014.